There are 3397 resources available
Invited Discussant LBA45 and 746MO
Presenter: Kosei Hasegawa
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previously treated ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study
Presenter: Kathleen Moore
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 1883MO and 1884MO
Presenter: Deborah Mukherji
Session: Mini oral session - Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
747MO - First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)
Presenter: Isabelle Ray-Coquard
Session: Mini oral session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Invited Discussant 745MO and 747MO
Presenter: Mansoor Raza Mirza
Session: Mini oral session - Gynaecological cancers
Resources:
Slides
Webcast
Introduction
Presenter: Ivana Bozovic Spasojevic
Session: Emerging issues in Adolescent and Young Adult (AYA) patients with malignant diseases
Resources:
Slides
Webcast
Presentation by Expert
Presenter: Manuela Schmidinger
Session: Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC)
Resources:
Slides
Webcast
Welcome and “set the scene”
Presenter: Georgina Long
Session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy
Resources:
Slides
Webcast
Discussion led by Chair
Presenter: Laurence Albiges
Session: Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC)
Resources:
Webcast
Yes
Presenter: Dirk Schadendorf
Session: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy
Resources:
Slides
Webcast